ISSN 1016-5169 | E-ISSN 1308-4488
Antiplatelet Treatment Preferences of a Group of Cardiologists from Türkiye: A Survey Research Study [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2024; 52(2): 116-124 | DOI: 10.5543/tkda.2023.54778

Antiplatelet Treatment Preferences of a Group of Cardiologists from Türkiye: A Survey Research Study

Özge Çetinarslan1, Mustafa Yenerçağ2, Mehdi Zoghi3, Asım Oktay Ergene4
1Department of Cardiology, Liv Hospital, Vadi İstanbul, İstanbul, Türkiye
2Department of Cardiology, Ordu University Faculty of Medicine, Türkiye
3Department of Cardiology, Ege University, Faculty of Medicine, Türkiye
4Department of Cardiology, Dokuz Eylül University, Faculty of Medicine, Türkiye

Deciding on the optimal duration of dual antiplatelet treatment (DAPT) remains a complex decision. This survey aims to explore the preferences for antiplatelet therapy and the daily routine regarding DAPT duration in coronary artery disease among a group of cardiologists in Türkiye.

Using an online questionnaire with 38 questions, the preferences of 314 cardiologists were collected. Qualitative descriptive characteristics of the answers received from the participants were examined.

Participating cardiologists mostly worked in training and research hospitals (51.59%) and university hospitals (21.66%). Participants primarily favored ticagrelor in patients undergoing PCI with a diagnosis of STEMI and NSTE-ACS (69.75% and 55.73% respectively). Clopidogrel was the most preferred P2Y12 treatment in patients with chronic coronary syndrome (CCS) after PCI (94.90%). Pre-treatment with a loading dose of a P2Y12 receptor inhibitor was administered to 57.01% of patients with NSTE-ACS, irrespective of the planned treatment strategy. In NSTE-ACS patients with low bleeding risk treated with PCI, 83.12% of participants recommended DAPT for 12 months and 14.65% for >12 months. In high-bleeding-risk NSTE-ACS patients treated with PCI, DAPT durations of six months (74.52%), three months (19.75%), and one month (5.73%) were chosen. Among CCS patients treated with PCI without an increased risk of bleeding, 12 months of DAPT was preferred by 68.15% of participants. Most participants (70.70%) were switching to a more potent P2Y12 receptor inhibitor therapy in emergency department clopidogrel-loaded patients with ACS.

The aim of this survey to capture a snapshot of the preferences of a group of cardiologists in Türkiye regarding DAPT treatment and duration. The responses were both in accordance and in conflict with the current guidelines.

Keywords: Acute coronary syndromes, antiplatelet agents, chronic coronary syndromes

How to cite this article
Özge Çetinarslan, Mustafa Yenerçağ, Mehdi Zoghi, Asım Oktay Ergene. Antiplatelet Treatment Preferences of a Group of Cardiologists from Türkiye: A Survey Research Study. Turk Kardiyol Dern Ars. 2024; 52(2): 116-124

Corresponding Author: Özge Çetinarslan, Türkiye
Manuscript Language: English

Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2024 Archives of the Turkish Society of Cardiology

Kare Publishing is a subsidiary of Kare Media.